Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

Exclusion Criteria

• •Six months or more (immediately prior to Screening Visit) without a menstrual period;
• •Prior hysterectomy;
• •Prior bilateral oophorectomy;
• •Pregnant or lactating females or women who are attempting or expecting to become pregnant at any time during the study;
• •Documented endometriosis, active pelvic inflammatory disease (PID), platelet dysfunction, or Von Willebrand's Disease;
• •Any history or diagnosis of gynecological cancer or cervical dysplasia of any grade including atypical squamous cells of undetermined significance (ASCUS) associated with Human Papilloma Virus (HPV);
• •Subject with diagnosed or suspected carcinoma of the breast, reproductive organs or any other organ system;
• •Subject with known active infection with HIV, Hepatitis A, B or C, Gonorrhea, or Chlamydia or previous history of auto-immune disease or positive serum antinuclear antibodies.